FBRX | Forte Biosciences, Inc. Stock Overview

(Stock Exchange: NASDAQ)

Day's Range	7.61 - 9.04
52 Week Range	4.11 - 28.68
Beta	2.64
Implied Volatility	471.77%
IV Rank	24.47%
Day's Volume	26,195
Average Volume	42,059
Shares Outstanding	6,393,320
Market Cap	49,612,163
Sector	Healthcare
Industry	Biotechnology
IPO Date	2017-04-13

Valuation
Profitability
Growth
Health
P/E Ratio	-0.47
Forward P/E Ratio	N/A
EPS	-16.38
1YR Price Target	N/A
Dividend Yield	N/A
Dividend Per Share	N/A
Dividend ExDate	N/A
Dividend PayDate	N/A
Employees	11
Country	USA
Website	FBRX

Forte Biosciences, Inc. operates as a clinical-stage biopharmaceutical company in the United States. It is developing FB-102 program that addresses various autoimmune diseases, such as vitiligo and alopecia areata. The company is headquartered in Dallas, Texas.

FBRX's peers: APRE, BCDA, NTRB, BYSI, CADL, CYCN, ABVC, DYAI, FBIOP, INDP, RZLT, TPST, CMRA, KTTA, BTTX, ZIVO, THRX, ERAS, AMTI, HOWL, EWTX, DBTX, CELC, CCCC, INKT, LGVN, NNVC, MLEC

*Chart delayed

Analyzing fundamentals for FBRX we got that it has weak fundamentals where Valuation is considered to be significantly overvalued, Profitability is unacceptably poor, Growth is desperately bad and Health is frighteningly weak. For more detailed analysis please see FBRX Fundamentals page.

Watching at FBRX technicals we can see that long-term trend is bullish, the same as bullish middle-term trend, as well as bullish short-term trend. More technicals details can be found on FBRX Technicals page.